Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
Clinical trial NCT02220894 · COMPLETED
Trial details
- NCT number
- NCT02220894
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-30
- Primary completion
- 2018-09-04
- Enrollment
- 1274
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.